KKR Entities Exit 5% Ownership Threshold in BridgeBio Pharma via Secondary Offering

KKR Genetic Disorder L.P., along with several affiliated entities including KKR & Co. Inc., filed Amendment No. 7 to their Schedule 13D for BridgeBio Pharma, Inc. (BBIO) to report a significant reduction in their holdings. On August 13, 2026, KKR Genetic Disorder L.P. entered into an underwriting agreement to sell 5,000,000 shares of Common Stock in a secondary offering at a net price of $77.415 per share. The transaction closed on August 17, 2026. Following this sale, the reporting persons collectively beneficially own 9,232,739 shares, representing approximately 4.7% of the company's outstanding common stock. This total includes 8,260,971 shares held directly and 971,768 shares issuable upon the conversion of Preferred Stock held by an alternative investment vehicle. Because the aggregate beneficial ownership has fallen below the 5% threshold, this filing serves as an exit filing for the reporting group. The reporting persons also entered into a 30-day lock-up agreement with the underwriters as part of the offering.